Quick Answer
Alto Neuroscience, Inc. reported Research And Development Expense of $45.62 million for the year ending 2025.
- Alto Neuroscience, Inc. showed a decrease of -2.9% in Research And Development Expense from 2024 to 2025.
- This data is from Alto Neuroscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $5.61 million | Q2 2023: $7.07 million | Q3 2023: $7.97 million | Q1 2024: $9.95 million | Q2 2024: $13.18 million | Q3 2024: $13.06 million | Q1 2025: $9.97 million | Q2 2025: $13.12 million | Q3 2025: $10.53 million.
- Over the full 3 years of available data (2023 to 2025), Alto Neuroscience, Inc.'s Research And Development Expense has grown by 50.6%.
- Historical annual values: Fiscal year 2025: $45.62 million | Fiscal year 2024: $47.00 million | Fiscal year 2023: $30.29 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: